$FATE Fate Therapeutics is Initiated to Outperform

$FATE Fate Therapeutics is Initiated by Wells Fargo to Outperform , according to the research report released to the investors. The shares recommendation by the Brokerage Firm was released on Dec-4-2015.

Many analysts have commented on the company rating. Raymond James initiates coverage on Fate Therapeutics, Inc. (NASDAQ:FATE) In a research note issued to the investors, the brokerage major announces a price-target of $8 per share.The shares have been rated Outperform. The rating by the firm was issued on October 6, 2015.

The company shares have rallied 8.27% from its 1 Year high price. On May 6, 2015, the shares registered one year high at $8.78 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $4.29 and the 200 Day Moving Average price is recorded at $5.97.

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) ended Tuesday session in red amid volatile trading. The shares closed down 0.01 points or 0.24% at $4.18 with 80,729 shares getting traded. Post opening the session at $4.21, the shares hit an intraday low of $4.1 and an intraday high of $4.235 and the price vacillated in this range throughout the day. The company has a market cap of $120 million and the number of outstanding shares have been calculated to be 28,716,570 shares. The 52-week high of Fate Therapeutics, Inc. (NASDAQ:FATE) is $8.781 and the 52-week low is $3.1235.

Fate Therapeutics, Inc. (NASDAQ:FATE): 4 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $9.75 in Fate Therapeutics, Inc. (NASDAQ:FATE). However, the stock price could fluctuate by $ 1.26 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $11 price target with the lower price estimate is calculated at $8.

Currently the company Insiders own 17.43% of Fate Therapeutics, Inc. shares according to the proxy statements. Institutional Investors own 63.91% of Fate Therapeutics, Inc. shares.

Fate Therapeutics, Inc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Its approaches utilize pharmacologic modalities, including small molecules and therapeutic proteins, and biological mechanisms to enhance the therapeutic potential of adult stem cells.


Get the Latest Videos

Small Cap Movers

Comstock Resources, Inc. Common

NYQ : CRK - 05 Feb, 11:48am
+0.105 (+8.203%) After Hours:
Open 1.220 Mktcap 66.09M
High 1.510 52wk Hight 6.840
Low 1.200 52wk Low 0.970
Vol 975567 Avg Vol 1.21M
Eps -4.600 P/e
Currency: USD

Argos Therapeutics, Inc.

NGM : ARGS - 05 Feb, 11:46am
-0.02 (-0.66%) After Hours:
Open 3.07 Mktcap 62.83M
High 3.15 52wk Hight 9.64
Low 3.00 52wk Low 1.61
Vol 25879 Avg Vol 106258
Eps -3.58 P/e
Currency: USD

Amyris, Inc.

NMS : AMRS - 05 Feb, 11:44am
+0.00 (+0.00%) After Hours:
Open 1.46 Mktcap 278.65M
High 1.49 52wk Hight 3.11
Low 1.44 52wk Low 1.13
Vol 6767 Avg Vol 156437
Eps -1.70 P/e
Currency: USD

Alliance Holdings GP, L.P.

NMS : AHGP - 05 Feb, 11:47am
-0.02 (-0.11%) After Hours:
Open 18.01 Mktcap 1.08B
High 18.37 52wk Hight 57.37
Low 17.45 52wk Low 12.43
Vol 48565 Avg Vol 169381
Eps 3.11 P/e 5.12
Currency: USD

Sign Up For Our Newsletter